NuVasive (NUVA) announced that proxy advisory firm Institutional Shareholder Services recommends that shareholders vote for the shareholder proposal to adopt the merger agreement with Globus Medical (GMED) at the upcoming special meeting of shareholders scheduled for April 27. "The merger "appears to have strategic merit, as the combined company will have increased scale with a complementary product portfolio and geographic footprint and addresses key strategic areas of focus for NUVA, including the lack of a robotics platform and an outsized cost structure," ISS stated in its report, according to NuVasive.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NUVA:
- Leading Independent Proxy Advisory Firm ISS Recommends NuVasive Shareholders Vote “FOR” the Proposed Merger with Globus Medical
- TD Cowen medical devices analyst to hold analyst/industry conference call
- NuVasive, Globus Medical continue to expect transaction to close mid-2023
- Canaccord upgrades Globus Medical with merger uncertainty priced in
- NuVasive gets FDA 510(k) clearance for Precice limb lengthening solution